Anidulafungin: An echinocandin antifungal

Expert Opinion on Investigational Drugs

Volumn 13, Issue 9, 2004, Pages 1183-1197

  Pfaller, Michael A ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

Anidulafungin; Antifungal; Echinocandin

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; AMPHOTERICIN B; ANIDULAFUNGIN; ANTIFUNGAL AGENT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CARBAMAZEPINE; CASPOFUNGIN; CORTISONE; CYCLOSPORIN; DEXAMETHASONE; FLUCONAZOLE; FUNGUS ANTIGEN; GAMMA GLUTAMYLTRANSFERASE; GLUCOCORTICOID; HYDROCORTISONE; ITRACONAZOLE; KETOCONAZOLE; NELFINAVIR; PHENYTOIN; PLACEBO; RIFAMPICIN; TRIAMCINOLONE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANTIFUNGAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASPERGILLUS; BILIRUBIN BLOOD LEVEL; CANDIDA; CANDIDIASIS; CLINICAL TRIAL; CONCENTRATION RESPONSE; CRYPTOCOCCUS NEOFORMANS; DISTRIBUTION VOLUME; DIZZINESS; DOSE LIVER FUNCTION RELATION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DEGRADATION; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SENSITIVITY; DRUG TOLERABILITY; DYSPNEA; FLUSHING; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEADACHE; HUMAN; HYPOKALEMIA; IN VITRO STUDY; IN VIVO STUDY; LIVER DYSFUNCTION; LUNG ASPERGILLOSIS; LUNG INFARCTION; MAINTENANCE DRUG DOSE; MINIMUM INHIBITORY CONCENTRATION; MULTIPLE DRUG DOSE; MYCOSIS; NAUSEA; NONHUMAN; SIDE EFFECT; SINGLE DRUG DOSE;

ANIMALS; ANTIBIOTICS, ANTIFUNGAL; ASPERGILLUS; CANDIDA; FUNGAL PROTEINS; HUMANS; PEPTIDES, CYCLIC;

EID: 4544256137     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.13.9.1183     Document Type: Article

References (85)

1. Anidulafungin: ECB, LY 303366, V-echinocandin, VEC, VER 002, VER-02. Drugs ,R&D (2003) 4:167-173.
2. MARTIN-MAZUELOS E: Anidulafungin. IDrugs (2003) 6:980-986.
3. KRISHNARAO TV, GALGIANI JN: Comparison of the in vitro activities of the echinocandin LY303366, the pneumocandin MK-0991, and fluconazole against Candida species and Cryptococcus neoformans. Antimicrob. Agents Chemother. (1997) 41:1957-1960.
4. ZHANEL GG, KARLOWSKY JA, HARDING GA et al.: In vitro activity of a new semisynthetic echinocandin, LY303366, against systemic isolates of Candida species, Cryptococcus neoformans, Blastomyces dermatitidis, and Aspergillus species. Antimicrob. Agents Chemother. (1997) 41:863-865.
5. GEORGOPARADAKOU NH: Update on antifungals targeted to the cell wall: focus on β-1, 3-glucan synthase inhibitors. Expert Opin. Investig. Drugs (2001) 10:269-280.
6. KURTZ MB, DOUGLAS CM: Lipopeptide inhibitors of fungal glucan synthase. J. Med. Vet. Mycol. (1997) 35:79-86.
7. JOHNSON MD, PERFECT JR. Caspofungin: first approved agent in a new class of antifungals. Expert Opin. Pharmacother. (2003) 4:807-823.
8. ARATHOON EG: Clinical efficacy of echinocandin antifungals. Curr. Opin. Infect. Dis. (2001) 14:685-691.
9. STOGNIEW M, PU F, HENKEL T, DOWELL J: Anidulafungin biotransformation in humans is by degradation not metabolism. Clin. Microbiol. Infect. (2003) 9:91.
10. DOWELL JA, KNEBEL W, LUDDEN T, STOGNIEW M, KRAUSE D, HENKEL T: Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal. J. Clin. Pharm. (2004) 44:590-598.
11. THYE D, KILFOIL G, HENKEL T: Anidulafungin: Safety and pharmacokinetics in subjects receiving concomitant cyclosporine. Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, USA (2001) Abstract A1836.
12. GRAYBILL JR: The echinocandins, first novel class of antifungals in two decades: Will they live up their promise? Int. J. Clin. Pract. (2001) 55:633-638.
13. DOUGLAS CM, D'IPPOLITO JA, SHEI GJ et al.: Identification of the FKS1 gene of Candida albicans as the essential target of 1, 3-β-D-glucan synthase inhibitors: Antimicrob. Agents Chemother. (1997) 41:2471-2479.
14. DEBONO M, GORDEE RS: Antibiotics that inhibit fungal cell wall development. Ann. Rev. Microbiol. (1994) 48:471-497.
15. HECTOR RF: Compounds active against cell walls of medically important fungi. Clin. Microbiol. Rev. (1993) 6:1-21.
16. AREVALO MP, CARRILLO-MUNOZ A-J, SALGADO J et al.: Antifungal activity of the echinocandin anidulafungin (VER002, LY-303366) against yeast pathogens: a comparative study with M27-A microdilution method. J. Antimicrob. Chemother. (2003) 51:163-166.
17. ESPINEL-INGROFF A: Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743, 872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J. Clin. Microbiol. (1998) 36:2950-2956.
18. MARCO F, PFALLER MA, MESSER SA, JONES RN: Activity of MK-0991 (L-743,872), a new echinocandin, compared with those of LY303366 and four other antifungal agents tested against blood stream isolates of Candida spp. Diagn, Microbiol. Infect. Dis. (1998) 31:33-37.
19. UZUN O, KOCAGOZ S, CETINKAYA Y, ARIKAN S, UNAL S: In vitro activity of a new echinocandin, LY-303366, compared with those of amphotericin B and fluconazole against clinical yeast isolates. Antimicrob. Agents Chemother. (1997) 41:1156-1157.
20. PFALLER MA, MARCO F, MESSER SA, JONES RN: In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743, 792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi. Diagn. Microbiol. Infect. Dis. (1998) 30:251-255.
21. VERWEIJ PE, OAKLEY KL, MORRISSEY J, MORRISSEY G, DENNING DW: Efficacy of LY303366 against amphotericin B-susceptible and -resistant Aspergillus fumigatus in a routine model of invasive aspergillosis. Antimicrob. Agents Chemother. (1998) 42:873-878.
22. ODABASI Z, PAETZNICK VL, RODRIQUEZ JR, CHEN E, OSTROSKY-ZEICHNER L: In vitro activity of anidulafungin against selected clinically important mold isolates. Antimicrob. Agents Chemother. (2004) 48:1912-1915.
23. BARTLETT MS, CURRENT WL, GOHEEN MP et al.: Semisynthetic echinocandins affect cell wall deposition of Pneumocystis carinii in vitro and in vivo. Antimicrob. Agents Chemother. (1996) 40:1811-1816.
24. CURRENT WL, BOYLAN CJ, RAAB PP: Antipneumocystis activity of LY303366 and other echinocandin B analogues. Abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, USA (1993) Abstract 368.
25. FELDMESSER M, KRESS Y, MEDNICK A, CASADEVALL A: The effects of the echinocandin analogue caspofungin on cell wall glucan synthesis by Cryptococcus neoformans. J. Infect. Dis. (2000) 182:1791-1795.
26. KURTZ MB, ABRUZZO G, FLATTERY A et al.: Characterization of echinocandin-resistant mutants of Candida albicans: genetic, biochemical, and virulence studies. Infect. Immun. (1996) 64:3244-3251.
27. OSHEROV N, MAY GS, ALBERT ND, KONTOYIANNIS DP: Overespression of Sbe2p, a Golgi protein, results in resistance to caspofungin in Saccaromyces cerevisiase. Antilmicrob. Agents Chemother. (2002) 46:2462-2469.
28. MORA-DUARTE J, BETTS R, ROTSTEIN C et al.: Comparison of caspofungin and amphotericin B for invasive candidiasis. N. Engl. J. Med. (2002) 347:2020-2029.
29. KRAUSE DS, REINHARDT J, VAZQUEZ JA et al.: Phase II, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia. Antimicrob. Agents Chemother. (2004) 48:2021-2024.
30. KRAUSE DS, SIMJEE AE, VAN RENSBURG C et al.: A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis. Clin. Infect. Dis. (2004) (In press).
31. VILLANUEVA A, GOTUZZO E, ARATHOON A et al.: A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am. J. Med. (2002) 113:294-299.
32. LAINE L: The natural history of esophageal candidiasis after successful treatment in patients with AIDS. Gastroenterology (1994) 107:744-746.
33. REX JH, PFALLER MA: Has antifungal susceptibility testing come of age? Clin. Infect. Dis. (2002) 35:982-989.
34. KLEPSER ME, ERNST EJ, ERNST ME, MESSER SA, PFALLER MA: Evaluation of endpoints for antifungal susceptibility determinations with LY303366. Antimicrob. Agents Cbemother. (1998) 42:1387-1391.
35. HERNANDEZ S, LOPEZ-RIBOT JL, NAJVAR LK, McCARTHY DI, BOCANEGRA R, GRAYBILL JR: Caspofungin resistance in Candida albicans. correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive Candida esophagitis. Antimicrob. Agents Chemother. (2004) 48:1382-1383.
36. GROLL AH, MICKIENE D, PETRAITIENE R et al.: Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling. Antimicrob. Agents Chemother. (2001) 45:2845-2855.
37. BROWN GL, WHITE RJ, TAUBEL J: Phase I dose optimization study for V-echinocandin. Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy Toronto, Canada (2000) Abstract 1105.
38. THYE D, SHEPHERD B, WHITE RJ, WESTON IE, HENKEL T: Anidulafungin: a Phase I study to identify the maximum tolerated dose in healthy volunteers. Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, USA (2001) Abstract 36.
39. DOWELL JA, PU F, LEE J, STOGNIEW M, KRAUSE D, HENKEL T: A clinical mass balance study of anidulafungin showing complete fecal elimination. Abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, USA (2003) Abstract A1576.
40. DOWELL J, STOGNIEW M, KRAUSE D: Anidulafungin dosage adjustments are not required for patients with hepatic and/or renal impairment. Clin. Microbiol. Infect. (2003) 9:1222.
41. THYE D, KILFOIL T, WHITE RJ, LASSETER K: Anidulafungin: Pharmacokinetics in subjects with mild and moderate hepatic impairment. Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, USA (2001) Abstract 34.
42. THYE D, KILFOIL G, KILFOIL T, HENKEL T: Anidulafungin: pharmacokinetics (PK) in subjects with severe hepatic impairment (HI). Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, USA (2001) Abstract A1392.
43. THYE D, MARBUY T, KILFOIL T, KILFOIL G, HENKEL T: Anidulafungin: pharmacokinetics in subjects receiving hemodialysis. Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, USA (2001) Abstract A1390.
44. THYE D, MARBUY T, KILFOIL G, KILFOIL G, HENKEL T: Anidulafungin: pharmacokinetics in subjects with renal impairment. Abstracts ofthe 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, USA (2001) Abstract A1391.
45. WHITE RJ, THYE D: Anidulafungin does not affect the metabolism of cyclosporine by human hepatic microsomes. Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy Chicago, USA (2001) Abstract 35.
46. CLEMONS K, SOBEL RA, STEVENS DA: Toxicity of LY303366, an echinocandin antifungal in mice pretreated with glucocorticoids. Antimicrob. Agents Chemother. (2000) 44:378-381.
47. STOGNIEW M, SENG JE, HOBERMAN A, HENKEL T: Anidulafungin, a novel antifungal agent, produces no overt toxicity when administered to DBA/2 and BALB/c mice, with or without cortisone acetate. Vicuron (Data on file).
48. ERNST ME, KLEPSER ME, WOLFE EJ, PFALLER MA: Antifungal dynamics of LY303366, an investigational echinocandin B analog, against Candida spp. Diagn. Microbiol. Infect. Dis. (1996) 26:125-131.
49. KARLOWSKY JA, HARDING GA, ZELENITSKY SA et al.: In vitro kill curves of a new semisynthetic echinocandin LY303366, against fluconazole sensitive and resistant Candida species. Antimicrob. Agents Chemother. (1997) 41:2576-2578.
50. PFALLER MA, SHEEHAN DJ, REX JH: Determination of fungicidal activities against yeasts and molds: lessons learned from bactericidal testing and the need for standardization. Clin. Microbiol. Rev. (2004) 17:268-280.
51. ROLING EE, KLEPSER ME, WASSON A, LEWIS RE, ERNST EJ, PFALLER MA: Antifungal activities of fluconazole, caspofungin (MK0991), and anidulafungin (LY303366) alone and in combination against Candida spp. and Cryptococcus neoformans via time-kill methods. Diagn. Microbiol. Infect. Dis. (2002) 43:13-17.
52. PETRAITIENE R, PETRAITIS V, GROLL AH et al.: Antifungal activity of LY303366, a novel echinocandin B, in experimental disseminated candidiasis in rabbits. Antimicrob. Agents Chemother. (1999) 43:2148-2155.
53. PETRAITIS V, PETRAITIENE R, GROLL A et al.: Antifungal efficacy, safety, and single dose plasma pharmacokinetics of LY3033666, a novel echinocandin B, in experimental pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob. Agents Chemother. (1998) 42:2898-2905.
54. ZECKNER D, BUTLER T, BOYLAN CJ, BOYLL B, LIN Y, RAAB P: LY303366 activity in a murine systemic candidiasis model. Abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington DC, USA (1993) Abstract 365.
55. ZECKNER D, BUTLER T, BOYLAN C et al.: LY303366 activity against systemic aspergillosis and histoplasmosis in murine models. Abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington DC, USA (1993) Abstract 369.
56. ANDES D: In vivo pharmacodynamics of antifungal drugs in treatment of candidiasis. Antimicrob. Agents Chemother. (2003) 47:1179-1186.
57. PETRAITIS V, PETRAITIENE R, GROLL AH et al.: Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob. Agents Chemother. (2002) 46:1857-1867.
58. CHANDRASEKAR PH, CUTRIGHT J, MANAVATHU E: Efficacy of voriconazole against invasive pulmonary aspergillosis in a guinea-pig model. J. Antimicrob. Chemother. (2000) 45:673-676.
59. KIRKPATRICK WR, PEREA S, COCO BJ, PATTERSON TF: Efficacy of ravuconazole (BMS-207147) in a guinea pig model of disseminated aspergillosis. J. Antimicrob. Chemother. (2002) 49:353-357.
60. PETRAITIENE R, PETRAITIS V, GROLL AH et al.: Antifungal activity and pharmacokinetics of posaconazole (SCH56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with glactomannan antigenemia. Antimicrob. Agents Chemother. (2001) 45:857-869.
61. KURTZ MB, HEATH IB, MARRINON J, DRIEKORN S, ONISHI J, DOUGLAS C: Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1, 3)-β-D-glucan synthase. Antimicrob. Agents Chemother. (1994) 38:1480-1489.
62. OAKLEY KL, MOORE CB, DENNING DW: In vitro activity of echinocandin antifungal agent LY303366 in comparison with itraconazole and amphotericin B against Aspergillus spp. Antimicrob. Agents Chemother. (1998) 42:2726-2730.
63. BOWMAN JC, FUCKS PS, KURTZ MB et al.: The antifungal echinocandin caspofungin acetate kills growing cells of aspergillus fumigatus in vitro. Antimicrob. Agents Chemother. (2002) 46:3001-3012.
64. ERNST EJ, KLEPSER ME, PFALLER MA: Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans. Antimicrob. Agents Chemother. (2000) 44:1108-1111.
65. OSTROSKY-ZEICHNER L, REX JH, PAPPAS PG et al.: Comparative antifungal susceptibility survey of 2,000 bloodstream isolates of Candida spp. from the United States. Antimicrob. Agents Chemother. (2003) 47:3149-3154.
66. PFALLER MA, MESSER SA, COFFMAN S: In vitro susceptibilities of clinical yeast isolates to a new echinocandin deriative, LY303366, and other antifungal agents. Antimicrob. Agents Chemother. (1997) 41:763-766.
67. ZELENITSKY S, KARLOWSKY J, HOBAN D et al.: Activity of an investigational echinocandin, LY303366, against fluconazole susceptible and resistant Canaida albicans in a multiple dose in vitro pharmacodynamic model. Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada (1997) Abstract F72.
68. ZHAENL GG, KARLOWSKY JA, ZELENITSKY S, TURIK MA, HOBAN DJ: Susceptibilities of candida species isolated from the lower gastrointestinal tracts of high-risk patients to the new semisynthetic echinocandin LY303366 and other agents. Antimicrob. Agents Chemother. (1998) 42:2446-2448.
69. BARTIZAL K, ODDS FC: Influences of methodological variables on susceptibility testing of caspofungin against Candida species and Apergillus fumigatus. Antimicrob. Agents Chemother. (2003) 47:2100-2107.
70. KLEPSER ME, ERNST EJ, ERNST ME, PFALLER MA: Growth medium effect on the antifungal activity of LY303366. Diagn. Microbiol. Infect Dis. (1997) 29:227-231.
71. PFALLER MA, MESSER SA, BOYKEN L et al.: Further standardization of broth microdilution methodology for in vitro susceptibility testing of caspofungin against Candida species by using an international collection of more than 3000 clinical isolates. J. Clin. Microbiol. (2004) 42:3117-3119.
72. REX JH, PFALLER MA, WALSH TJ et al.: Antifungal susceptibility testing: practical aspects and current challenges. Clin. Microbiol. Rev. (2001) 14:643-658.
73. ODDS FC, MOTYL M, ANDRADE R et al.: Susceptibility testing with caspofungin against Candida and Aspergillus species: an interlaboratory comparison. Antimicrob. Agents Chemother. (2004) (In Press).
74. NATIONAL COMMITTEE FOR CLINICAL LABORATORY STANDARDS: Rtference method for broth dilution antifungal susceptibility testing of yeasts. approved standard (2nd edition). National Committee For Clinical laboratory Standards, Wayne, PA, USA (2002) M27-A2.
75. PFALLER MA, DIEKEMA DJ, MESSER SA, HOLLIS RJ, JONES RN: In vitro activities of caspofungin compared with those of fluconazole and itraconazole against 3,959 clinical isolates of candida spp., including 157 fluconazole-resistant isolates. Antimicrob. Agents Chemother. (2003) 47:1068-1071.
76. JOHNSON EM, GOLDSTEIN BP, DAVEY KG, FRASER MA: Comparison of the in vitro activity of anidulafungin with amphotericin B, caspofungin, fluconazole, itraconazole, and voriconazole against a panel of 780 yeasts obtained from five European centres. Clin. Microbiol. Infect. (2004) 10(Suppl. 13):113.
77. NATIONAL COMMITTEE FOR CLINICAL LABORATORY STANDARDS: Reference method for broth dilution antifungal susceptibility testing of filamentous fungi: approved standard M38-A. National Committee for Clinical Laboratory Standards, Wayne, PA (2002).
78. WALSH TJ, GROLL A, HIEMENZ J, FLEMING R, ROILIDES E, ANAISSIE E: Infections due to emerging and uncommon medically important fungal pathogens. Clin. Microbiol. Infect. Dis., (2004) 10(Suppl. 1):48-66.
79. TURNER WW, CURRENT WL: Echinocandin antifungal agents. In: Biotechnology of Industrial Antibiotics (2nd edition). Strohl WR (Ed.), Marcel Dekker, Inc., New York, USA (1997):315-334.
80. PETRAITIS V, PETRAITIENE R, GROLL AH et al.: Dosage-dependent antifungal efficacy of V-echinocandin (LY303366) against experimental fluconazole-resistant oropharyngeal and esophageal candidiasis. Antimicrob. Agents Chemother. (2001) 45:471-479.
81. ROBERTS J, SCHOCK K, MARINO S, ANDRIOLE VT: Efficacacies of two new antifungal agents, the triazole ravuconazole and the echinocandin LY-303366, in an experimental model of invasive aspergillosis. Antimicrob. Agents Chemother. (2000) 44:3381-3388.
82. BROWN GL, WHITE RJ, TURIK M: Phase II, randomized open label study of two intravenous dosing regimens of V-echinocandin in the treatment of esophageal candidiasis. Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada (2000) Abstract 1104.
83. ANAISSIE EJ, VARTIVARIAN SE, ABI-SAID O et al.: Fluconazole versus amphotericin B in the treatment of hematogenous candidiasis: a matched cohort study. Am. J. Med. (1996) 101:170-176.
84. REX JH, BENNETT JE, SUGAR AM et al.: A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N. Engl. J. Med. (1994) 331:1325-1330.
85. REX JH, PAPPAS PG, KARCHMER AW et al.: A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in non-neutropenic subjects. Clin. Infect. Dis. (2003) 36:1221-1228.